← Oncology Approval Tracker

FDA DECISION ·

Talzenna + Xtandi

talazoparib + enzalutamide · Pfizer

FDA approvalNew or expanded indicationProstate cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For metastatic castration-resistant prostate cancer with a homologous recombination repair gene mutation.

LAMPGEN ANALYSIS

Why it matters

The combination extended PARP inhibition into an HRR-defined prostate cancer regimen.

What research teams should watch

Verify the individual HRR alteration and schedule blood-count monitoring for the combination.

PRIMARY RECORDS

Sources